I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Capital Investment Advisors LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 12.1% during ...

Brookstone Capital Management cut its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 9.9% in the fourth quarter, ...

Tensions rise between the USA and Denmark as Trump suggests tariffs over failed Greenland acquisition talks. Danish business leaders express concerns, stressing strategic ties with the USA, while ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.

Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Columbus joins the states of Arkansas, California, Kansas, Kentucky, Minnesota and Mississippi and other cities and counties ...

Massachusetts is the latest state going after insulin makers and the intermediaries officials accuse of price gouging. Why it ...